[3] The company has research and development facilities in Martinsried, Germany and San Diego, California, as well as offices in Zug, Switzerland, and Morrisville, North Carolina.

Developed as the non-replicating smallpox and mpox vaccine, MVA-BN is approved in Canada as Imvamune,[8] in the European Union, as Imvanex,[9] and the United States as Jynneos.

[13] The company has worked for several years with the NIAID[14] on the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases.

[19] In October 2019, it was announced that Bavarian Nordic would acquire travel vaccines Rabipur(/Rabavert) for rabies and Encepur for tick-borne encephalitis (TBE) from GlaxoSmithKline (GSK).

[20][21] In February 2023, it was announced that Bavarian Nordic would acquire travel vaccines Vivotif for typhoid fever and Vaxchora for cholera, in addition to a late-stage candidate for chikungunya, from Emergent BioSolutions.